Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely
contributing to tumor immune evasion. The deregulation mainly arises from the potentiated …

Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …

Background MET (also known as hepatocyte growth factor receptor) signalling is a key
driver of papillary renal cell carcinoma (PRCC). Given that no optimal therapy for metastatic …

PURPOSE COSMIC-021 is evaluating cabozantinib plus atezolizumab in patients with solid
tumors. We report results from patients with advanced clear cell (cc) and non–clear cell (ncc) …

Vascularization is fundamental to the growth and spread of tumor cells to distant sites. As a
consequence, angiogenesis, the sprouting of new blood vessels from existing ones, is a …

The treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized
over the past two decades, bringing forth an era in which more than a dozen therapeutic …

Chromophobe renal cell carcinoma (chRCC) is the third most common type of RCC with
distinct biology compared to other kidney cancer subtypes. The heterogeneity between the …

Importance Patients with brain metastases from renal cell carcinoma (RCC) have been
underrepresented in clinical trials, and effective systemic therapy is lacking. Cabozantinib …

PURPOSE In this multicenter phase II trial, we evaluated atezolizumab combined with
bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant histology or …

Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types
respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) …